Petalmed Pharma

Bevatas 300 mg Injection contains Bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is used as an anti-angiogenic therapy in various cancers by inhibiting the formation of new blood vessels that support tumor growth.

Bevatas is supplied as a sterile, preservative-free concentrate for intravenous infusion. The product is manufactured following stringent GMP/WHO-GMP standards to ensure purity, safety, and high therapeutic reliability for international markets.